CTNI-36. SINGLE INSTITUTE REPORT OF DORDAVIPRONE (ONC 201) PLUS BEVACIZUMAB COMBINATION THERAPY ON THE EXPANDED ACCESS PROTOCOL (ONC 028) Article Swipe

PDF

Naveed Wagle , Akanksha Sharma , Fen Feng , Santosh Kesari ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1093/neuonc/noaf201.0532

BACKGROUND Dordaviprone (ONC201), an oral, CNS penetrant, targeted small molecule ClpP agonist and DRD2 antagonist, is currently under investigation in patients with H3K27M-mutant diffuse glioma. Expanded access programs (EAPs) have offered a means to gain real-world experience with dordaviprone ahead of potential regulatory approval. Here we describe our experience implementing the combination of bevacizumab and dordaviprone in this EAP setting. METHODS ONC028, the dordaviprone EAP protocol in the US, was designed to provide access for patients that were ineligible for dordaviprone clinical trials. We retrospectively analyzed clinical features and treatment experience of 16 patients receiving dordaviprone (625 mg once weekly) plus bevacizumab as part of ONC028 at Providence/St. John’s Cancer Institute. RESULTS Patients ranged in age from 20-59 years. Patients treated with combination dordaviprone + bevacizumab remained on dordaviprone therapy for an average of 7.5 months, 4 patients remain on dordaviprone with follow up time ranging from 6-29 months as of the data cutoff. The combination therapy did not result in any additional reported side effects outside of those anticipated from each agent as monotherapy. No deterioration in quality of life was observed in patients receiving the combination. CONCLUSIONS This single-center experience provides insight into the safety and treatment duration associated with the combination of dordaviprone and bevacizumab in real-world patients enrolled in ONC028. No negative impact on quality of life was reported with combination therapy. The side effect profile of the combination therapy did not reveal any increased toxicity. These data highlight a potential role for the addition of bevacizumab during dordaviprone treatment.

Related Topics

Truth And Reconciliation Commission Of Canada

Alanis Morissette

2025 Nba Draft

Concepts

No concepts available.

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1093/neuonc/noaf201.0532
PDF: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf
OA Status: bronze
OpenAlex ID: https://openalex.org/W4416141316

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4416141316

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1093/neuonc/noaf201.0532

Digital Object Identifier
Title: CTNI-36. SINGLE INSTITUTE REPORT OF DORDAVIPRONE (ONC 201) PLUS BEVACIZUMAB COMBINATION THERAPY ON THE EXPANDED ACCESS PROTOCOL (ONC 028)

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-11-01

Full publication date if available
Authors: Naveed Wagle, Akanksha Sharma, Fen Feng, Santosh Kesari

List of authors in order
Landing page: https://doi.org/10.1093/neuonc/noaf201.0532

Publisher landing page
PDF URL: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: bronze

Open access status per OpenAlex
OA URL: https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf

Direct OA link when available
Cited by: 0

Total citation count in OpenAlex

Full payload

id	https://openalex.org/W4416141316
doi	https://doi.org/10.1093/neuonc/noaf201.0532
ids.doi	https://doi.org/10.1093/neuonc/noaf201.0532
ids.openalex	https://openalex.org/W4416141316
fwci
type	article
title	CTNI-36. SINGLE INSTITUTE REPORT OF DORDAVIPRONE (ONC 201) PLUS BEVACIZUMAB COMBINATION THERAPY ON THE EXPANDED ACCESS PROTOCOL (ONC 028)
biblio.issue	Supplement_5
biblio.volume	27
biblio.last_page	v134
biblio.first_page	v134
is_xpac	False
apc_list.value	4612
apc_list.currency	USD
apc_list.value_usd	4612
apc_paid
language	en
locations[0].id	doi:10.1093/neuonc/noaf201.0532
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S106908163
locations[0].source.issn	1522-8517, 1523-5866
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	1522-8517
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Neuro-Oncology
locations[0].source.host_organization	https://openalex.org/P4310311648
locations[0].source.host_organization_name	Oxford University Press
locations[0].source.host_organization_lineage	https://openalex.org/P4310311648, https://openalex.org/P4310311647
locations[0].source.host_organization_lineage_names	Oxford University Press, University of Oxford
locations[0].license
locations[0].pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Neuro-Oncology
locations[0].landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0532
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5035365137
authorships[0].author.orcid	https://orcid.org/0009-0007-8072-0348
authorships[0].author.display_name	Naveed Wagle
authorships[0].countries	US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I4210134119
authorships[0].affiliations[0].raw_affiliation_string	Pacific Neuroscience Insitute, Santa Monica, USA
authorships[0].institutions[0].id	https://openalex.org/I4210134119
authorships[0].institutions[0].ror	https://ror.org/03n07ce29
authorships[0].institutions[0].type	healthcare
authorships[0].institutions[0].lineage	https://openalex.org/I4210134119
authorships[0].institutions[0].country_code	US
authorships[0].institutions[0].display_name	Pacific Heart Institute
authorships[0].author_position	first
authorships[0].raw_author_name	Naveed Wagle
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Pacific Neuroscience Insitute, Santa Monica, USA
authorships[1].author.id	https://openalex.org/A5076592441
authorships[1].author.orcid	https://orcid.org/0000-0002-4331-5526
authorships[1].author.display_name	Akanksha Sharma
authorships[1].countries	US
authorships[1].affiliations[0].institution_ids	https://openalex.org/I4210134119
authorships[1].affiliations[0].raw_affiliation_string	Pacific Neuroscience Insitute, Santa Monica, USA
authorships[1].institutions[0].id	https://openalex.org/I4210134119
authorships[1].institutions[0].ror	https://ror.org/03n07ce29
authorships[1].institutions[0].type	healthcare
authorships[1].institutions[0].lineage	https://openalex.org/I4210134119
authorships[1].institutions[0].country_code	US
authorships[1].institutions[0].display_name	Pacific Heart Institute
authorships[1].author_position	middle
authorships[1].raw_author_name	Akanksha Sharma
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Pacific Neuroscience Insitute, Santa Monica, USA
authorships[2].author.id	https://openalex.org/A5086924875
authorships[2].author.orcid
authorships[2].author.display_name	Fen Feng
authorships[2].countries	US
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210104056
authorships[2].affiliations[0].raw_affiliation_string	Saint John Cancer Insitute, Santa Monica, USA
authorships[2].institutions[0].id	https://openalex.org/I4210104056
authorships[2].institutions[0].ror	https://ror.org/01gcc9p15
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I4210104056, https://openalex.org/I94396219
authorships[2].institutions[0].country_code	US
authorships[2].institutions[0].display_name	Saint John's Health Center
authorships[2].author_position	last
authorships[2].raw_author_name	Frances Feng
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Saint John Cancer Insitute, Santa Monica, USA
authorships[3].author.id	https://openalex.org/A5063863193
authorships[3].author.orcid	https://orcid.org/0000-0003-3772-6000
authorships[3].author.display_name	Santosh Kesari
authorships[3].countries	US
authorships[3].affiliations[0].institution_ids	https://openalex.org/I4210134119
authorships[3].affiliations[0].raw_affiliation_string	Pacific Neuroscience Insitute, Santa Monica, USA
authorships[3].institutions[0].id	https://openalex.org/I4210134119
authorships[3].institutions[0].ror	https://ror.org/03n07ce29
authorships[3].institutions[0].type	healthcare
authorships[3].institutions[0].lineage	https://openalex.org/I4210134119
authorships[3].institutions[0].country_code	US
authorships[3].institutions[0].display_name	Pacific Heart Institute
authorships[3].author_position	middle
authorships[3].raw_author_name	Santosh Kesari
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Pacific Neuroscience Insitute, Santa Monica, USA
has_content.pdf	True
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf
open_access.oa_status	bronze
open_access.any_repository_has_fulltext	False
created_date	2025-11-11T00:00:00
display_name	CTNI-36. SINGLE INSTITUTE REPORT OF DORDAVIPRONE (ONC 201) PLUS BEVACIZUMAB COMBINATION THERAPY ON THE EXPANDED ACCESS PROTOCOL (ONC 028)
has_fulltext	False
is_retracted	False
updated_date	2025-11-28T06:13:12.813674
primary_topic
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1093/neuonc/noaf201.0532
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S106908163
best_oa_location.source.issn	1522-8517, 1523-5866
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	1522-8517
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Neuro-Oncology
best_oa_location.source.host_organization	https://openalex.org/P4310311648
best_oa_location.source.host_organization_name	Oxford University Press
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310311648, https://openalex.org/P4310311647
best_oa_location.source.host_organization_lineage_names	Oxford University Press, University of Oxford
best_oa_location.license
best_oa_location.pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Neuro-Oncology
best_oa_location.landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0532
primary_location.id	doi:10.1093/neuonc/noaf201.0532
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S106908163
primary_location.source.issn	1522-8517, 1523-5866
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	1522-8517
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Neuro-Oncology
primary_location.source.host_organization	https://openalex.org/P4310311648
primary_location.source.host_organization_name	Oxford University Press
primary_location.source.host_organization_lineage	https://openalex.org/P4310311648, https://openalex.org/P4310311647
primary_location.source.host_organization_lineage_names	Oxford University Press, University of Oxford
primary_location.license
primary_location.pdf_url	https://academic.oup.com/neuro-oncology/article-pdf/27/Supplement_5/v134/65255074/noaf201.0532.pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Neuro-Oncology
primary_location.landing_page_url	https://doi.org/10.1093/neuonc/noaf201.0532
publication_date	2025-11-01
publication_year	2025
referenced_works_count	0
abstract_inverted_index.+	125
abstract_inverted_index.4	137
abstract_inverted_index.a	32, 244
abstract_inverted_index.16	93
abstract_inverted_index.No	176, 215
abstract_inverted_index.We	84
abstract_inverted_index.an	4, 132
abstract_inverted_index.as	103, 150, 174
abstract_inverted_index.at	107
abstract_inverted_index.in	20, 57, 67, 115, 161, 178, 184, 209, 213
abstract_inverted_index.is	16
abstract_inverted_index.mg	98
abstract_inverted_index.of	41, 53, 92, 105, 134, 151, 168, 180, 205, 220, 231, 250
abstract_inverted_index.on	128, 140, 218
abstract_inverted_index.to	34, 72
abstract_inverted_index.up	144
abstract_inverted_index.we	46
abstract_inverted_index.7.5	135
abstract_inverted_index.CNS	6
abstract_inverted_index.EAP	59, 65
abstract_inverted_index.The	155, 227
abstract_inverted_index.US,	69
abstract_inverted_index.age	116
abstract_inverted_index.and	13, 55, 89, 198, 207
abstract_inverted_index.any	162, 238
abstract_inverted_index.did	158, 235
abstract_inverted_index.for	75, 80, 131, 247
abstract_inverted_index.not	159, 236
abstract_inverted_index.our	48
abstract_inverted_index.the	51, 63, 68, 152, 187, 196, 203, 232, 248
abstract_inverted_index.was	70, 182, 222
abstract_inverted_index.(625	97
abstract_inverted_index.6-29	148
abstract_inverted_index.ClpP	11
abstract_inverted_index.DRD2	14
abstract_inverted_index.Here	45
abstract_inverted_index.This	190
abstract_inverted_index.data	153, 242
abstract_inverted_index.each	172
abstract_inverted_index.from	117, 147, 171
abstract_inverted_index.gain	35
abstract_inverted_index.have	30
abstract_inverted_index.into	195
abstract_inverted_index.life	181, 221
abstract_inverted_index.once	99
abstract_inverted_index.part	104
abstract_inverted_index.plus	101
abstract_inverted_index.role	246
abstract_inverted_index.side	165, 228
abstract_inverted_index.that	77
abstract_inverted_index.this	58
abstract_inverted_index.time	145
abstract_inverted_index.were	78
abstract_inverted_index.with	22, 38, 122, 142, 202, 224
abstract_inverted_index.20-59	118
abstract_inverted_index.These	241
abstract_inverted_index.agent	173
abstract_inverted_index.ahead	40
abstract_inverted_index.means	33
abstract_inverted_index.oral,	5
abstract_inverted_index.small	9
abstract_inverted_index.those	169
abstract_inverted_index.under	18
abstract_inverted_index.(EAPs)	29
abstract_inverted_index.Cancer	110
abstract_inverted_index.ONC028	106
abstract_inverted_index.access	27, 74
abstract_inverted_index.during	252
abstract_inverted_index.effect	229
abstract_inverted_index.follow	143
abstract_inverted_index.impact	217
abstract_inverted_index.months	149
abstract_inverted_index.ranged	114
abstract_inverted_index.remain	139
abstract_inverted_index.result	160
abstract_inverted_index.reveal	237
abstract_inverted_index.safety	197
abstract_inverted_index.years.	119
abstract_inverted_index.METHODS	61
abstract_inverted_index.ONC028,	62
abstract_inverted_index.ONC028.	214
abstract_inverted_index.RESULTS	112
abstract_inverted_index.agonist	12
abstract_inverted_index.average	133
abstract_inverted_index.cutoff.	154
abstract_inverted_index.diffuse	24
abstract_inverted_index.effects	166
abstract_inverted_index.glioma.	25
abstract_inverted_index.insight	194
abstract_inverted_index.months,	136
abstract_inverted_index.offered	31
abstract_inverted_index.outside	167
abstract_inverted_index.profile	230
abstract_inverted_index.provide	73
abstract_inverted_index.quality	179, 219
abstract_inverted_index.ranging	146
abstract_inverted_index.therapy	130, 157, 234
abstract_inverted_index.treated	121
abstract_inverted_index.trials.	83
abstract_inverted_index.weekly)	100
abstract_inverted_index.Abstract	0
abstract_inverted_index.Expanded	26
abstract_inverted_index.John’s	109
abstract_inverted_index.Patients	113, 120
abstract_inverted_index.addition	249
abstract_inverted_index.analyzed	86
abstract_inverted_index.clinical	82, 87
abstract_inverted_index.describe	47
abstract_inverted_index.designed	71
abstract_inverted_index.duration	200
abstract_inverted_index.enrolled	212
abstract_inverted_index.features	88
abstract_inverted_index.molecule	10
abstract_inverted_index.negative	216
abstract_inverted_index.observed	183
abstract_inverted_index.patients	21, 76, 94, 138, 185, 211
abstract_inverted_index.programs	28
abstract_inverted_index.protocol	66
abstract_inverted_index.provides	193
abstract_inverted_index.remained	127
abstract_inverted_index.reported	164, 223
abstract_inverted_index.setting.	60
abstract_inverted_index.targeted	8
abstract_inverted_index.therapy.	226
abstract_inverted_index.(ONC201),	3
abstract_inverted_index.approval.	44
abstract_inverted_index.currently	17
abstract_inverted_index.highlight	243
abstract_inverted_index.increased	239
abstract_inverted_index.potential	42, 245
abstract_inverted_index.receiving	95, 186
abstract_inverted_index.toxicity.	240
abstract_inverted_index.treatment	90, 199
abstract_inverted_index.BACKGROUND	1
abstract_inverted_index.Institute.	111
abstract_inverted_index.additional	163
abstract_inverted_index.associated	201
abstract_inverted_index.experience	37, 49, 91, 192
abstract_inverted_index.ineligible	79
abstract_inverted_index.penetrant,	7
abstract_inverted_index.real-world	36, 210
abstract_inverted_index.regulatory	43
abstract_inverted_index.treatment.	254
abstract_inverted_index.CONCLUSIONS	189
abstract_inverted_index.antagonist,	15
abstract_inverted_index.anticipated	170
abstract_inverted_index.bevacizumab	54, 102, 126, 208, 251
abstract_inverted_index.combination	52, 123, 156, 204, 225, 233
abstract_inverted_index.Dordaviprone	2
abstract_inverted_index.combination.	188
abstract_inverted_index.dordaviprone	39, 56, 64, 81, 96, 124, 129, 141, 206, 253
abstract_inverted_index.implementing	50
abstract_inverted_index.monotherapy.	175
abstract_inverted_index.H3K27M-mutant	23
abstract_inverted_index.deterioration	177
abstract_inverted_index.investigation	19
abstract_inverted_index.single-center	191
abstract_inverted_index.Providence/St.	108
abstract_inverted_index.retrospectively	85
cited_by_percentile_year
countries_distinct_count	1
institutions_distinct_count	4
citation_normalized_percentile